Patient-centered, Optimal Integration of Survivorship and Palliative Care

Launched by MASSACHUSETTS GENERAL HOSPITAL · May 20, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a new supportive care program called POISE for patients with advanced Non-small Cell Lung Cancer (NSCLC). The main goal is to see if this program can help patients feel less anxious about their future, boost their confidence in managing their cancer, and improve their understanding of what to expect as they go through treatment. Participants will either receive the POISE program, which includes four visits with a trained specialist in palliative care, or continue with standard care. They will also complete three surveys to share their experiences.

To be eligible for this trial, participants must be at least 18 years old, be patients at the MGH Cancer Center, and have been diagnosed with metastatic NSCLC with specific genetic changes (like EGFR or ALK mutations) within the last six months. They also need to be receiving targeted therapy and should be able to communicate in English or Spanish. However, those with serious mental health issues, urgent palliative needs, or who are pregnant or incarcerated cannot participate. This study is currently recruiting participants and aims to provide valuable insights into how supportive care can improve the quality of life for patients facing this challenging diagnosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 18 or older
• • MGH Cancer Center patient
• • Within 6 months of diagnosis of metastatic NSCLC with oncogenic driver mutation (EGFR, ALK, ROS1, RET)
• • Receiving targeted therapy
• • Ability to respond in English or Spanish
• Exclusion Criteria:
• • Cognitive impairment or serious mental illness that limits ability to provide informed consent
• • Need for urgent palliative care or hospice referral
• • Pregnant women
• • Prisoners